Identification and Evaluation of Possible Approaches to Addressing Nitrosamine Impurities in Drugs (U01)

Department of Health and Human Services

Description

The FDA is offering a grant to support research on reducing risks from nitrosamine impurities in human drugs. The goal is to enhance safety while maintaining access to important medications. The recipient of this grant will also explore how to continue this research in collaboration with industry, non-profits, or academia after the funding ends.

The Food and Drug Administration's (FDA), Center for Drug Evaluation and Research (CDER), Office of New Drugs (OND), is announcing this Funding Opportunity Announcement (FOA) for a Cooperative Agreement.

 

The proposed work directly supports the U.S. FDA’s stated g…

Source

Grant ID

FOR-FD-24-008

Agency

Department of Health and Human Services

Subcategory/Subagency

Food and Drug Administration

Eligibility

The following categories of applicants are invited to apply:

  • Small businesses
  • Independent school districts
  • City or township governments
  • County governments
  • State governments
  • Special district governments
  • Others (see text field entitled "Additional Information on Eligibility" for clarification)
  • Public and State controlled institutions of higher education
  • Private institutions of higher education
  • Native American tribal governments (Federally recognized)
  • For profit organizations other than small businesses
  • Public housing authorities/Indian housing authorities
  • Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
  • Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
  • Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"
  • Native American tribal organizations (other than Federally recognized tribal governments)
Additional Eligibility Information
Applicant organizations may submit more than one application, provided that each application is scientifically distinct.The FDA will not accept duplicate or highly overlapping applications under review at the same time. This means that the FDA will not accept:•A new (A0) application that is submitted before issuance of the summary statement from the review of an overlapping new (A0) or resubmission (A1) application.•A resubmission (A1) application that is submitted before issuance of …
Awards & Funding

Award Ceiling

$350,000

Award Floor

$350,000

Funding Amount

Discretionary

Links
Similar opportunities

Save this opportunity and explore more

Share Opportunity

Share this opportunity with others.
Anyone with this link can view the opportunity details.